PDSB PDS Biotechnology Corp

Nasdaq pdsbiotech.com


$ 0.92 $ -0.02 (-2.04 %)    

Friday, 17-Oct-2025 15:59:34 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 0.9263
$ 0.96
$ 0.95 x 34
$ 1.05 x 6,000
$ 0.91 - $ 0.97
$ 0.85 - $ 3.48
344,154
na
43.2M
$ 2.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-28-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-18-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 02-21-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 08-01-2018 06-30-2018 10-Q
30 05-01-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-01-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 03-02-2017 12-31-2016 10-K
36 11-01-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-03-2016 03-31-2016 10-Q
39 03-08-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pds-biotech-reports-295-month-median-overall-survival-in-phase-2-trial-for-advanced-head-and-neck-cancer-says-encouraging-efficacy-signal-observed-in-difficult-to-treat-category-of-advanced-head-and-neck-cancer-patients

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) al...

 pds-biotechnology-corp-files-for-mixed-shelf-of-up-to-200m

- SEC Filing

 pds-biotechnology-reports-median-overall-survival-of-393-months-in-hpv16-positive-head-and-neck-cancer-patients

Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizum...

 pds-biotechnology-q2-eps-021-beats-023-estimate

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-reiterates-buy-on-pds-biotechnology-maintains-13-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $13 pri...

 hc-wainwright--co-reiterates-buy-on-pds-biotechnology-maintains-13-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $13 pri...

 pds-biotechnology-to-host-virtual-ko-event-to-discuss-unmet-need-and-current-treatment-landscape-for-recurrentmetastatic-hpv16-positive-hnscc

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences o...

 pds-biotech-reports-durable-30-month-median-overall-survival-in-1l-recurrentmetastatic-hnscc-highlights-urgent-need-in-rapidly-rising-hpv16-positive-cases

Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION